At the 14th St. Gallen International Breast Cancer Conference 2015, Prof Sibylle Loibl (German Breast Group, Neu-Isenburg, Germany) discusses recent advances in neoadjuvant therapy for breast cancer, including the rationale for the use of the surrogate endpoint, pathological complete response (pCR), for survival in neoadjuvant studies.
Join our mailing list
To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now